title: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
abstract: In this Phase I trial, patients' peripheral blood dendritic cells were pulsed with peptides eluted from the surface of autologous glioma cells. Three biweekly intradermal vaccinations of peptide-pulsed dendritic cells were administered to seven patients with glioblastoma multiforme and two patients with anaplastic astrocytoma. Dendritic cell vaccination elicited systemic cytotoxicity in four of seven tested patients. Robust intratumoral cytotoxic and memory T-cell infiltration was detected in two of four patients who underwent reoperation after vaccination. This Phase I study demonstrated the feasibility, safety, and bioactivity of an autologous peptide-pulsed dendritic cell vaccine for patients with malignant glioma.
authors.affiliation: Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA. blackk@cshs.org
authors.forename: J S
authors.initials: JS
authors.lastname: Yu
authors.forename: C J
authors.initials: CJ
authors.lastname: Wheeler
authors.forename: P M
authors.initials: PM
authors.lastname: Zeltzer
authors.forename: H
authors.initials: H
authors.lastname: Ying
authors.forename: D N
authors.initials: DN
authors.lastname: Finger
authors.forename: P K
authors.initials: PK
authors.lastname: Lee
authors.forename: W H
authors.initials: WH
authors.lastname: Yong
authors.forename: F
authors.initials: F
authors.lastname: Incardona
authors.forename: R C
authors.initials: RC
authors.lastname: Thompson
authors.forename: M S
authors.initials: MS
authors.lastname: Riedinger
authors.forename: W
authors.initials: W
authors.lastname: Zhang
authors.forename: R M
authors.initials: RM
authors.lastname: Prins
authors.forename: K L
authors.initials: KL
authors.lastname: Black
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology; D001254:Astrocytoma / Q000276:immunology* / Q000628:therapy; D001932:Brain Neoplasms / Q000276:immunology* / Q000628:therapy; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D005260:Female; D005909:Glioblastoma / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007156:Immunologic Memory / Q000276:immunology; D016233:Immunotherapy, Active; D016219:Immunotherapy, Adoptive; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines